Next Article in Journal / Special Issue
Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors
Previous Article in Journal
Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings
Article Menu

Export Article

Open AccessReview
Antibodies 2017, 6(4), 16; https://doi.org/10.3390/antib6040016

Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy

1
University Bourgogne Franche-Comté, INSERM, LNC UMR1231, F-21079 Dijon, France
2
CovalAb, Research Department, 11 Avenue Albert Einstein, 69100 Villeurbanne, Lyon, France
3
INSERM, UMR1231, Laboratoire d’Excellence LipSTIC, F-21079 Dijon, France
*
Author to whom correspondence should be addressed.
Received: 15 September 2017 / Revised: 16 October 2017 / Accepted: 19 October 2017 / Published: 25 October 2017
(This article belongs to the Special Issue Cancer Antibodies)
View Full-Text   |   Download PDF [4410 KB, uploaded 28 October 2017]   |  

Abstract

Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing ligand (TRAIL), the only cytokine of the family capable of eradicating selectively cancer cells, led to the development of numerous TRAIL derivatives targeting death receptor 4 (DR4) and death receptor 5 (DR5) for cancer therapy. With a few exceptions, preliminary attempts to use recombinant TRAIL, agonistic antibodies, or derivatives to target TRAIL agonist receptors in the clinic have been fairly disappointing. Nonetheless, a tremendous effort, worldwide, is being put into the development of novel strategic options to target TRAIL receptors. Antibodies and derivatives allow for the design of novel and efficient agonists. We summarize and discuss here the advantages and drawbacks of the soar of TRAIL therapeutics, from the first developments to the next generation of agonistic products, with a particular insight on new concepts. View Full-Text
Keywords: TRAIL; death-receptor targeting; ligand; cancer therapy; apoptosis; antibody; bi-specific; antibody drug conjugate; chimeric antigen receptor; scFv TRAIL; death-receptor targeting; ligand; cancer therapy; apoptosis; antibody; bi-specific; antibody drug conjugate; chimeric antigen receptor; scFv
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Dubuisson, A.; Micheau, O. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. Antibodies 2017, 6, 16.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top